Cantor Fitzgerald Estimates Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Disc Medicine in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($5.24) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $85.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.07) per share.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15.

Other equities research analysts also recently issued reports about the company. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $66.00 to $110.00 in a report on Monday, November 4th. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price for the company in a research note on Tuesday, November 5th. Jefferies Financial Group began coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price target on the stock. Scotiabank boosted their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $88.20.

Disc Medicine Stock Up 3.9 %

Shares of NASDAQ IRON opened at $60.52 on Wednesday. The stock’s 50 day moving average price is $62.82 and its two-hundred day moving average price is $53.66. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60. The stock has a market capitalization of $1.80 billion, a P/E ratio of -15.21 and a beta of 0.75.

Insiders Place Their Bets

In other Disc Medicine news, CEO John D. Quisel sold 12,791 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the transaction, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William Richard White sold 7,136 shares of the stock in a transaction on Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The disclosure for this sale can be found here. In the last 90 days, insiders sold 85,758 shares of company stock worth $5,400,990. Insiders own 4.24% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. SG Americas Securities LLC boosted its holdings in shares of Disc Medicine by 66.0% in the fourth quarter. SG Americas Securities LLC now owns 8,076 shares of the company’s stock valued at $512,000 after acquiring an additional 3,212 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock worth $799,000 after purchasing an additional 2,257 shares during the period. Exome Asset Management LLC boosted its stake in Disc Medicine by 5.8% during the 3rd quarter. Exome Asset Management LLC now owns 64,516 shares of the company’s stock valued at $3,170,000 after purchasing an additional 3,516 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of Disc Medicine by 38.7% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock valued at $961,000 after purchasing an additional 5,458 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock worth $23,333,000 after buying an additional 70,983 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.